Drug Quantity Management Policy — Oral Substance P/Neurokinin-1 (NK1) Receptor Antagonists
Cigna Drug Quantity Management policy that sets per‑prescription quantity limits and medically necessary exceptions for oral NK1 receptor antagonist antiemetics (Akynzeo, aprepitant/Emend, rolapitant/Varubi) for members of Cigna-administered health benefit plans.
No material clinical or coverage changes in this revision.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.